Left Ventricular Outflow Tract Obstruction (LVOTO)
Definition
Dynamic obstruction to LV systolic outflow caused primarily by systolic anterior motion (SAM) of the mitral valve leaflet contacting the interventricular septum. Defined by a peak instantaneous Doppler gradient ≥30 mmHg; the threshold for pharmacological and invasive treatment is ≥50 mmHg.
Epidemiology
- Present in ~70% of HCM patients (resting or provocable). (sources/esc-cmp-2023
very high) - Major cause of exertional symptoms and a contributor to SCD risk in HCM. (sources/esc-cmp-2023
very high) - Gradients are dynamic — vary with heart rate, blood pressure, volume status, activity, medications, food, and alcohol intake. (sources/HCM-AHA-2024
very high)
Pathophysiology
- SAM mechanism: Mitral leaflet is displaced anteriorly during systole, contacts the hypertrophied septum, and creates a dynamic obstruction that worsens as systole progresses. (sources/esc-cmp-2023
very high) - Sarcomere hypercontractility is the underlying driver — excess cross-bridge cycling generates the hyperdynamic, hypercontractile state that promotes SAM and gradient generation. This is the pharmacological target of cardiac myosin inhibitors. (sources/aficamten-maplehcm-nejm-2025
very high) - Aggravating factors: tachycardia, reduced preload (dehydration, diuretics, vasodilators), reduced afterload, positive inotropes — all worsen the gradient. (sources/HCM-AHA-2024
very high) - Pressure contour: Dynamic LVOTO produces a spike-and-dome aortic contour (rapid initial upstroke at AV opening, then late systolic pressure drop as obstruction develops) with late-peaking LV pressure — distinct from fixed valvular obstruction. (sources/hemodynamics-circ-2012
high)
Diagnosis
Echocardiographic Assessment
- Protocol (Class I, Level B): 2D Doppler echo at rest + Valsalva manoeuvre (sitting, semi-supine; then standing if no gradient provoked). If symptomatic and resting/Valsalva gradient <50 mmHg: exercise stress echocardiography. (sources/esc-cmp-2023
very high) - Gradient thresholds: ≥30 mmHg = obstruction present; ≥50 mmHg = haemodynamically significant (treatment threshold). (sources/esc-cmp-2023
very high) - Transoesophageal echocardiography for mechanism clarification before invasive procedures. (sources/esc-cmp-2023
very high) - Dobutamine pharmacological provocation is not advised — not physiological, poorly tolerated. (sources/esc-cmp-2023
very high)
Invasive Hemodynamic Assessment (Cardiac Catheterisation)
- Spike-and-dome aortic contour: Dynamic LVOTO → rapid initial upstroke then late systolic pressure drop; fixed valvular AS → parvus et tardus upstroke from time of AV opening. (sources/hemodynamics-circ-2012
high) - Braunwald-Brockenborough sign: On the post-PVC beat, HCM with dynamic LVOTO shows a decrease in aortic pulse pressure (enhanced obstruction from post-extrasystolic potentiation); fixed valvular AS shows an increase — key diagnostic differentiator in the cath lab. (sources/hemodynamics-circ-2012
high) - Isoproterenol provocation: When Valsalva and PVC induction fail to provoke a gradient ≥50 mmHg, isoproterenol infusion (β1+β2 stimulation) simulates exercise and can unmask labile outflow obstruction before septal ablation; also used post-ablation to confirm adequate gradient reduction. (sources/hemodynamics-circ-2012
high) - Technical caution: Catheters frequently entrap in hypertrophied hyperdynamic ventricles → erroneous pressure measurements; transseptal approach preferred; if retrograde catheter used, multipurpose/Rodriquez catheter (distal side holes) preferred over long-sidehole pigtail catheters. (sources/hemodynamics-circ-2012
high)
Management — Pharmacological
ESC 2023 Stepwise Algorithm (Class I unless noted)
- Non-vasodilating beta-blockers (Class I, Level B) — first-line; titrated to maximum tolerated dose.
- Verapamil or diltiazem (Class I, Level B) — if beta-blockers contraindicated or ineffective.
- Disopyramide added to beta-blockers (Class I, Level B) — QTc monitoring required (reduce dose if QTc >500 ms).
- Mavacamten (Class IIa, Level A) — when above therapy is insufficient; echocardiographic surveillance of LVEF required. (sources/esc-cmp-2023
very high)
AHA 2024 Step-3 (all Class I, Level B-R — differs from ESC)
- Options at step 3 are equivalent: cardiac myosin inhibitor (adults only) OR disopyramide + AV nodal blocker OR SRT — elevating mavacamten to Class I parity with disopyramide and SRT. (sources/HCM-AHA-2024
very high) - Verapamil — Class III: Harm in patients with severe dyspnoea at rest, hypotension, very high resting gradients (>100 mmHg), or children <6 weeks of age. (sources/HCM-AHA-2024
very high) - Vasodilators and digoxin: discontinuation reasonable in symptomatic obstructive HCM as they can worsen LVOTO (Class IIb). (sources/HCM-AHA-2024
very high)
Agents to Avoid (both guidelines)
- Digoxin, nitrates, phosphodiesterase inhibitors — all may exacerbate LVOTO. (sources/esc-cmp-2023
very high) - Low-dose diuretics may cautiously improve exertional dyspnoea (Class IIb, Level C); hypovolaemia must be avoided. (sources/esc-cmp-2023
very high)
Management — Invasive (Septal Reduction Therapy)
- Indication (ESC 2023): LVOTO ≥50 mmHg + NYHA III–IV symptoms refractory to maximal drug therapy. (sources/esc-cmp-2023
very high) - Indication (AHA 2024): Severe dyspnoea/chest pain (usually NYHA III–IV) + peak LVOT gradient ≥50 mmHg at rest or with physiologic provocation + SAM + sufficient anterior septal thickness for the procedure. (sources/HCM-AHA-2024
very high) - Options: Surgical myectomy and alcohol septal ablation (ASA) — see concepts/Septal-Reduction-Therapy.
- Asymptomatic LVOTO: No indication for invasive procedures; pharmacological treatment may be considered in selected cases (Class IIb). (sources/esc-cmp-2023
very high)
Clinical Evidence
EXPLORER-HCM (Lancet 2020) — Mavacamten vs Placebo on Background Therapy
- Phase 3, double-blind, placebo-controlled RCT (N=251; 68 centres; 13 countries; 30 weeks). Mavacamten (5–15 mg/day) vs placebo added to background beta-blocker or CCB (92% on background therapy; disopyramide excluded). Primary composite endpoint (pVO2 + NYHA improvement): 37% vs 17% (+19.4%; p=0.0005). (sources/mavacamten-explorer-hcm-lancet-2020
very high) - LVOT gradient: Post-exercise gradient reduced by −35.6 mmHg vs placebo (p<0.0001); 74% of mavacamten patients achieved post-exercise LVOT <50 mmHg vs 21% placebo. Complete response (all LVOT <30 mmHg + NYHA I): 27% vs 1%. (sources/mavacamten-explorer-hcm-lancet-2020
very high) - Functional outcomes: NYHA ≥1 class improvement 65% vs 31%; 50% reached NYHA class I vs 21% placebo. KCCQ-CSS +9.1 points; VE/VCO2 slope improved by −2.6 regardless of beta-blocker use. (sources/mavacamten-explorer-hcm-lancet-2020
very high) - Biomarkers: NT-proBNP 80% greater reduction vs placebo; hs-cTnI 41% greater reduction — suggesting disease-modifying effect beyond haemodynamics. (sources/mavacamten-explorer-hcm-lancet-2020
very high) - Beta-blocker interaction: Primary endpoint benefit attenuated in beta-blocker users (+8.7% vs +52.6% in non-users) — attributed to chronotropic limitation on pVO2, NOT to attenuation of the haemodynamic effect (LVOT reduction and NYHA improvement were consistent regardless). (sources/mavacamten-explorer-hcm-lancet-2020
very high) - Safety: LVEF <50% in 5.7% of mavacamten patients; all recovered after temporary discontinuation. No sudden death or serious HF in mavacamten group. (sources/mavacamten-explorer-hcm-lancet-2020
very high)
SEQUOIA-HCM (NEJM 2024) — Aficamten vs Placebo on Background Therapy
- Phase 3, double-blind, placebo-controlled RCT (N=282; 101 sites; 24 weeks). Aficamten (5–20 mg/day) added to background therapy (beta-blockers 61%; disopyramide 13%) vs placebo. Primary endpoint: peak VO2 placebo-corrected difference +1.7 ml/kg/min (P<0.001). (sources/aficamten-sequoiahcm-nejm-2024
very high) - All 10 secondary endpoints significant: NYHA ≥1 class improvement 58.5% vs 24.3%; KCCQ-CSS +7 points; Valsalva LVOTO gradient −50 mmHg; post-Valsalva LVOTO <30 mmHg in 49.3% vs 3.6%; SRT eligibility 78 fewer days (95% CI −100 to −56). (sources/aficamten-sequoiahcm-nejm-2024
very high) - NT-proBNP ~80% reduction (geometric mean proportional change 0.20 vs 1.00). Gradient reduction seen by week 2 (−20 mmHg). All benefits reversed after 4-week washout. (sources/aficamten-sequoiahcm-nejm-2024
very high) - Benefit consistent regardless of background beta-blocker use — contrast with mavacamten (EXPLORER-HCM showed attenuated pVO2 benefit in beta-blocker users). (sources/aficamten-sequoiahcm-nejm-2024
very high) - Safety: LVEF <50% in 3.5% (transient, no HF exacerbations); serious AEs 5.6% vs 9.3%. (sources/aficamten-sequoiahcm-nejm-2024
very high)
MAPLE-HCM (NEJM 2025) — Aficamten vs Metoprolol as Monotherapy
- First head-to-head RCT of cardiac myosin inhibitor vs beta-blocker as monotherapy (N=175; 24 weeks; double-blind double-dummy). Aficamten (5–20 mg/day) superior to metoprolol (50–200 mg/day) on peak VO2 (difference +2.3 ml/kg/min; P<0.001), Valsalva LVOTO gradient (−40.7 vs −3.8 mmHg), NT-proBNP (81% relative difference), LAVi, NYHA class, and KCCQ-CSS. (sources/aficamten-maplehcm-nejm-2025
very high) - Metoprolol does not improve LVOTO gradient (−3.8 mmHg) despite reducing HR by 23.4 bpm. NT-proBNP increased with metoprolol; LAVi increased; peak VO2 decreased. Beta-blocker benefit appears to be largely chronotropic (subjective symptom relief), not haemodynamic. (sources/aficamten-maplehcm-nejm-2025
very high) - Safety: LVEF <50%: 1% aficamten vs 0% metoprolol; safety profiles otherwise similar. (sources/aficamten-maplehcm-nejm-2025
very high)
Contradictions / Open Questions
- Mavacamten positioning — AHA Class I vs ESC Class IIa: AHA 2024 elevates mavacamten to a Class I step-3 option equivalent to disopyramide or SRT. ESC 2023 positions mavacamten as Class IIa, step 4 — below disopyramide and only after it has failed or is not tolerated. No head-to-head trial comparing mavacamten directly to disopyramide or SRT exists. The two tiers reflect committee interpretation of the same EXPLORER and VALOR trial data. (sources/HCM-AHA-2024, sources/esc-cmp-2023)
- Verapamil — Class III in specific scenarios (AHA) vs Class I (ESC): AHA 2024 designates verapamil as Class III: Harm in HCM patients with severe dyspnoea at rest, hypotension, very high resting gradients (>100 mmHg), or children <6 weeks. ESC 2023 lists verapamil/diltiazem as Class I second-line for LVOTO. The same drug is simultaneously Class I (ESC) and contraindicated in specific HCM phenotypes (AHA). (sources/HCM-AHA-2024, sources/esc-cmp-2023)
- Beta-blockers as first-line Class I vs MAPLE-HCM evidence for inferiority to aficamten monotherapy: Both AHA 2024 and ESC 2023 designate beta-blockers as Class I step-1 therapy; cardiac myosin inhibitors are positioned as step-2/3 add-on. However, MAPLE-HCM (NEJM 2025) demonstrated aficamten monotherapy is superior to metoprolol monotherapy on all objective endpoints. Metoprolol did not significantly reduce LVOTO gradient (−3.8 mmHg) despite HR reduction of 23.4 bpm. The mechanistic rationale for beta-blockers as first-line is challenged — they achieve subjective improvement via chronotropy but fail to address sarcomere hypercontractility or dynamic obstruction. Current guideline recommendations have not been updated in light of MAPLE-HCM. (sources/aficamten-maplehcm-nejm-2025, sources/HCM-AHA-2024, sources/esc-cmp-2023)
Connections
- Related to entities/HCM
- Related to entities/Mavacamten
- Related to entities/Aficamten
- Related to concepts/Septal-Reduction-Therapy
- Related to concepts/HCM-Risk-SCD